How to appeal a UnitedHealthcare pediatric oncology denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for pediatric oncology

Cited policy: UnitedHealthcare Oncology Medical Policy: CAR-T Cell Therapy (Kymriah)

Tisagenlecleucel for r/r B-ALL ages ≤25 per FDA label. REMS-enrolled center. Prior 2+ lines therapy or post-HSCT relapse. Insurer site-of-care steerage to specific FACT-accredited centers.

How UnitedHealthcare denies pediatric oncology — and how to counter it

Where UnitedHealthcare pushes back: 1) Experimental / investigational; 2) Step therapy: re-induction chemo first; 3) Out-of-network CAR-T center.

Counter-arguments that hold up: Kymriah FDA approval Aug 30, 2017 — NOT experimental. ELIANA NEJM 2018 — 81% CR/CRi at 3 mo with durable remissions. NCCN Category 1 r/r ALL. CMS NTAP + outpatient APC payment established 2018-2019. Step-therapy with re-induction chemo in MRD+ post-2nd-relapse contraindicated. Out-of-network: pediatric CAR-T cert restricted to ~30 centers; SCA at in-network rates per network adequacy + Stock Blood 2008 superior pediatric outcomes.

What UnitedHealthcare typically denies for pediatric oncology

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For pediatric oncology, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the pediatric oncology treatments most often flagged for prior auth, step therapy, or medical necessity review:

• COG trial enrollment
• CAR-T (Kymriah)
• Proton therapy
• Pediatric immunotherapy
• Targeted therapy
• ALL chemo regimen

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.